Exc face tum deep < 2 cm
CPT 21013 covers the surgical removal of a deep tumor or lesion in the face that is smaller than 2 centimeters (about three-quarters of an inch). This is for deeper tissue masses, not surface-level skin removals.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Document tumor depth explicitly in operative report with measurement from skin surface to deepest extent, noting involvement of subfascial or muscular layers
Impact: Prevents $150-200 downcoding to simple skin excision codes (11440-11446) which reimburse 40-60% less
Measure and record the excised diameter (not the defect size) in the operative note and pathology requisition to justify size-based coding
Impact: Critical for defending against payer audits; size documentation errors account for 35% of surgical denials and can result in downcoding from $520.13 to lower-paying codes
Bill in non-facility setting when appropriate (office-based surgery suite or ASC owned by practice) rather than hospital outpatient
Impact: Increases reimbursement by $124.53 per case ($520.13 vs $395.60) due to higher practice expense RVUs
Verify global period (90 days for 21013) and avoid billing E/M services during postoperative period unless modifier 24 is appropriately applied for unrelated conditions
Impact: Prevents automatic denials and recoupment; improper global period billing triggers audits with potential $200-400 recoupment per incident
When excising multiple facial tumors, bill each with modifier 59 or XS if different anatomic sites and not contiguous
Impact: Secures full payment for each separate excision rather than bundled payment; can add $395-520 per additional distinct site
Submit pathology report with claim or have readily available for audits to substantiate deep tissue involvement and tumor characteristics
Reduces denial rate by 25-30%; pathology confirmation is often requested in post-payment audits and lack of documentation triggers recoupment
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.